Published in Antimicrob Agents Chemother on July 01, 1995
DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev (1997) 9.69
Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother (1996) 7.10
Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin Microbiol Rev (1997) 6.98
Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother (1996) 4.42
Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J Bacteriol (1996) 4.34
Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother (2006) 4.19
High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother (1996) 4.04
Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob Agents Chemother (1996) 3.95
Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother (1996) 3.86
Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob Agents Chemother (1997) 3.83
Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (1997) 3.50
Subtle genetic changes enhance virulence of methicillin resistant and sensitive Staphylococcus aureus. BMC Microbiol (2007) 3.25
DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci U S A (1997) 2.99
Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli. Antimicrob Agents Chemother (1996) 2.91
Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1996) 2.84
Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother (1999) 2.75
Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob Agents Chemother (1996) 2.48
Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother (1999) 2.47
Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene. Antimicrob Agents Chemother (1996) 2.42
Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. Antimicrob Agents Chemother (1996) 2.31
Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother (1996) 2.22
Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity. Antimicrob Agents Chemother (1998) 1.97
Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC. Antimicrob Agents Chemother (1998) 1.91
Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones. Antimicrob Agents Chemother (1998) 1.86
Characterization of NorR protein, a multifunctional regulator of norA expression in Staphylococcus aureus. J Bacteriol (2003) 1.81
Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection. PLoS Pathog (2010) 1.74
Increased expression of fibronectin-binding proteins by fluoroquinolone-resistant Staphylococcus aureus exposed to subinhibitory levels of ciprofloxacin. Antimicrob Agents Chemother (1997) 1.71
Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus. Antimicrob Agents Chemother (1997) 1.70
Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions. Antimicrob Agents Chemother (2000) 1.66
Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones. Antimicrob Agents Chemother (1999) 1.63
Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro. Antimicrob Agents Chemother (1998) 1.61
In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin. Antimicrob Agents Chemother (2003) 1.59
Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother (1997) 1.58
Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus. Antimicrob Agents Chemother (1997) 1.55
Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis. Antimicrob Agents Chemother (1998) 1.40
Evidence for the existence of a multidrug efflux transporter distinct from NorA in Staphylococcus aureus. Antimicrob Agents Chemother (2000) 1.37
Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains. Antimicrob Agents Chemother (1998) 1.36
Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone. Antimicrob Agents Chemother (2002) 1.34
Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins. Antimicrob Agents Chemother (1999) 1.34
Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother (2001) 1.32
Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis. Antimicrob Agents Chemother (2000) 1.32
Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus. Antimicrob Agents Chemother (1999) 1.31
Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained In vitro. Antimicrob Agents Chemother (1998) 1.31
Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Antimicrob Agents Chemother (1998) 1.31
Differences in LexA regulon structure among Proteobacteria through in vivo assisted comparative genomics. Nucleic Acids Res (2004) 1.30
Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756. Antimicrob Agents Chemother (2001) 1.30
Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus. Antimicrob Agents Chemother (1999) 1.29
Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins. Antimicrob Agents Chemother (2001) 1.27
Characterization of Mycoplasma hominis mutations involved in resistance to fluoroquinolones. Antimicrob Agents Chemother (1997) 1.27
Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase. Antimicrob Agents Chemother (2000) 1.25
Induction of fibronectin-binding proteins and increased adhesion of quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin. Antimicrob Agents Chemother (2000) 1.23
Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. Antimicrob Agents Chemother (2001) 1.20
Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments. Antimicrob Agents Chemother (2004) 1.17
NorA functions as a multidrug efflux protein in both cytoplasmic membrane vesicles and reconstituted proteoliposomes. J Bacteriol (2002) 1.10
Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus. Antimicrob Agents Chemother (2001) 1.09
Development of resistance to ciprofloxacin, rifampin, and mupirocin in methicillin-susceptible and -resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother (2000) 1.09
In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus. Antimicrob Agents Chemother (2001) 1.08
Accumulation of mutations in both gyrB and parE genes is associated with high-level resistance to novobiocin in Staphylococcus aureus. Antimicrob Agents Chemother (2005) 1.05
Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis. Antimicrob Agents Chemother (1998) 1.04
Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Staphylococcus aureus. BMC Microbiol (2011) 1.04
Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob Agents Chemother (2003) 1.03
Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin. Antimicrob Agents Chemother (2005) 1.03
Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium. Antimicrob Agents Chemother (1999) 1.03
Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA. Antimicrob Agents Chemother (1999) 1.02
Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones. Antimicrob Agents Chemother (2002) 1.01
Fluoroquinolone action in mycobacteria: similarity with effects in Escherichia coli and detection by cell lysate viscosity. Antimicrob Agents Chemother (1996) 1.01
Cloning and nucleotide sequences of the topoisomerase IV parC and parE genes of Mycoplasma hominis. Antimicrob Agents Chemother (1998) 1.01
Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases. Antimicrob Agents Chemother (1998) 1.01
Topoisomerase sequences of coagulase-negative staphylococcal isolates resistant to ciprofloxacin or trovafloxacin. Antimicrob Agents Chemother (1999) 1.00
Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis. Thorax (1998) 0.99
DNA cleavage activities of Staphylococcus aureus gyrase and topoisomerase IV stimulated by quinolones and 2-pyridones. Antimicrob Agents Chemother (1999) 0.99
Impact of ciprofloxacin exposure on Staphylococcus aureus genomic alterations linked with emergence of rifampin resistance. Antimicrob Agents Chemother (2011) 0.97
Effects of rice seed surface sterilization with hypochlorite on inoculated Burkholderia vietnamiensis. Appl Environ Microbiol (2001) 0.97
Glycosylated flavones as selective inhibitors of topoisomerase IV. Antimicrob Agents Chemother (1997) 0.97
Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases. Antimicrob Agents Chemother (1998) 0.95
Sparfloxacin selects gyrase mutations in first-step Mycoplasma hominis mutants, whereas ofloxacin selects topoisomerase IV mutations. Antimicrob Agents Chemother (1999) 0.95
Quinolone resistance mutations in the GrlB protein of Staphylococcus aureus. Antimicrob Agents Chemother (1998) 0.95
Multidrug Efflux Pumps in Staphylococcus aureus: an Update. Open Microbiol J (2013) 0.95
A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II. Antimicrob Agents Chemother (2004) 0.93
In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci. Antimicrob Agents Chemother (2001) 0.90
Ciprofloxacin dimers target gyrase in Streptococcus pneumoniae. Antimicrob Agents Chemother (2004) 0.90
Examination of methicillin-resistant and methicillin-susceptible Staphylococcus aureus mutants with low-level fluoroquinolone resistance. Antimicrob Agents Chemother (1998) 0.89
Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones. Antimicrob Agents Chemother (2006) 0.88
Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1998) 0.88
Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus. Antimicrob Agents Chemother (2007) 0.87
Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance. Antimicrob Agents Chemother (2006) 0.86
An approach to identifying drug resistance associated mutations in bacterial strains. BMC Genomics (2012) 0.86
In vitro activities of 13 fluoroquinolones against Staphylococcus aureus isolates with characterized mutations in gyrA, gyrB, grlA, and norA and against wild-type isolates. Antimicrob Agents Chemother (1999) 0.85
Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. Antimicrob Agents Chemother (2007) 0.85
Sequence of quinolone resistance-determining region of gyrA gene for clinical isolates and for an in vitro-selected quinolone-resistant strain of Coxiella burnetii. Antimicrob Agents Chemother (1996) 0.85
Cloning and sequencing of a novel gene (recG) that affects the quinolone susceptibility of Staphylococcus aureus. Antimicrob Agents Chemother (1997) 0.84
Ofloxacin-loaded liposomes: in vitro activity and drug accumulation in bacteria. Antimicrob Agents Chemother (2000) 0.84
Clerocidin selectively modifies the gyrase-DNA gate to induce irreversible and reversible DNA damage. Nucleic Acids Res (2008) 0.84
Analysis of grlA mutations in clinical isolates of Staphylococcus aureus with different levels of quinolone resistance. Antimicrob Agents Chemother (1998) 0.83
Sequence analysis of the gyrA and parC homologues of a wild-type strain of Vibrio parahaemolyticus and its fluoroquinolone-resistant mutants. Antimicrob Agents Chemother (1999) 0.83
Introduction of a norA promoter region mutation into the chromosome of a fluoroquinolone-susceptible strain of Staphylococcus aureus using plasmid integration. Antimicrob Agents Chemother (1999) 0.83
Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones. Antimicrob Agents Chemother (1999) 0.82
The new fluoroquinolones: A critical review. Can J Infect Dis (1999) 0.82
Topoisomerase mutations in fluoroquinolone-resistant and methicillin-susceptible and -resistant clinical isolates of Staphylococcus aureus. Antimicrob Agents Chemother (1998) 0.81
NorA plasmid resistance to fluoroquinolones: role of copy number and norA frameshift mutations. Antimicrob Agents Chemother (1996) 0.81
The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. Nature (1983) 19.44
Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother (1990) 11.71
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbiol (1994) 7.89
Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J Bacteriol (1990) 7.61
Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother (1994) 6.39
Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones. Antimicrob Agents Chemother (1989) 5.80
Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Mol Microbiol (1994) 5.49
DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli. J Bacteriol (1990) 5.13
Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions. J Biol Chem (1993) 4.54
Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1993) 4.27
Routes of quinolone permeation in Escherichia coli. Antimicrob Agents Chemother (1988) 4.09
Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital. Antimicrob Agents Chemother (1989) 4.04
Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob Agents Chemother (1994) 3.96
Nucleotide sequence of the Staphylococcus aureus gyrB-gyrA locus encoding the DNA gyrase A and B proteins. J Bacteriol (1992) 3.95
A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus. J Bacteriol (1991) 3.70
Mechanisms of fluoroquinolone resistance in Staphylococcus aureus. J Infect Dis (1991) 3.66
Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome. Antimicrob Agents Chemother (1994) 3.57
Detection of gyrA gene mutations associated with ciprofloxacin resistance in methicillin-resistant Staphylococcus aureus: analysis by polymerase chain reaction and automated direct DNA sequencing. Antimicrob Agents Chemother (1992) 3.36
Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations. Antimicrob Agents Chemother (1984) 3.04
Methicillin-resistant strains of Staphylococcus aureus resistant to quinolones. J Clin Microbiol (1989) 2.80
Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob Agents Chemother (1994) 2.76
A comparison of methods used for measuring the accumulation of quinolones by Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus. J Antimicrob Chemother (1991) 2.64
Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates. Antimicrob Agents Chemother (1994) 2.47
Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalis. Antimicrob Agents Chemother (1994) 2.43
Characterization of fluoroquinolone-resistant mutants of escherichia coli selected in vitro. Antimicrob Agents Chemother (1994) 2.24
Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureus. Antimicrob Agents Chemother (1993) 2.11
The interaction between coumarin drugs and DNA gyrase. Mol Microbiol (1993) 1.80
Ciprofloxacin-resistant Staphylococcus aureus. Lancet (1985) 1.67
Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1994) 1.60
In-vitro selection of bacteria resistant to the 4-quinolone agents. J Antimicrob Chemother (1987) 1.54
In vivo selection during pefloxacin therapy of a mutant of Staphylococcus aureus with two mechanisms of fluoroquinolone resistance. Antimicrob Agents Chemother (1994) 0.93
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbiol (1994) 7.89
Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. Antimicrob Agents Chemother (1996) 2.31
Purification and characterization of S-adenosyl-L-methionine: uroporphyrinogen III methyltransferase from Pseudomonas denitrificans. J Bacteriol (1989) 2.25
Burkholderia pseudomallei traced to water treatment plant in Australia. Emerg Infect Dis (2000) 2.15
Spinal tuberculosis in adults. A study of 103 cases in a developed country, 1980-1994. Medicine (Baltimore) (1999) 2.11
Genetic and sequence analysis of an 8.7-kilobase Pseudomonas denitrificans fragment carrying eight genes involved in transformation of precorrin-2 to cobyrinic acid. J Bacteriol (1990) 1.92
Cloning and analysis of genes involved in coenzyme B12 biosynthesis in Pseudomonas denitrificans. J Bacteriol (1989) 1.82
Assay, purification, and characterization of cobaltochelatase, a unique complex enzyme catalyzing cobalt insertion in hydrogenobyrinic acid a,c-diamide during coenzyme B12 biosynthesis in Pseudomonas denitrificans. J Bacteriol (1992) 1.67
Nucleotide sequence, organisation and structural analysis of the products of genes in the nirB-cysG region of the Escherichia coli K-12 chromosome. Eur J Biochem (1990) 1.66
Autoantibodies to the constitutive 73-kD member of the hsp70 family of heat shock proteins in systemic lupus erythematosus. J Exp Med (1988) 1.54
A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther (1997) 1.53
Purification and characterization of cobyrinic acid a,c-diamide synthase from Pseudomonas denitrificans. J Bacteriol (1990) 1.39
Plasmid DNA size does not affect the physicochemical properties of lipoplexes but modulates gene transfer efficiency. Nucleic Acids Res (1999) 1.38
Genetic analysis, nucleotide sequence, and products of two Pseudomonas denitrificans cob genes encoding nicotinate-nucleotide: dimethylbenzimidazole phosphoribosyltransferase and cobalamin (5'-phosphate) synthase. J Bacteriol (1991) 1.36
A bifunctional protein from Pseudomonas denitrificans carries cobinamide kinase and cobinamide phosphate guanylyltransferase activities. J Bacteriol (1991) 1.32
Virus-sized self-assembling lamellar complexes between plasmid DNA and cationic micelles promote gene transfer. Proc Natl Acad Sci U S A (1997) 1.29
Assay and purification of S-adenosyl-L-methionine:precorrin-2 methyltransferase from Pseudomonas denitrificans. J Bacteriol (1990) 1.28
Production of pro-inflammatory cytokines correlates with the symptoms of acute sickness behaviour in humans. Psychol Med (2004) 1.24
Pristinamycin I biosynthesis in Streptomyces pristinaespiralis: molecular characterization of the first two structural peptide synthetase genes. J Bacteriol (1997) 1.24
Fossilization of an ancient (devonian) soft-bodied worm. Science (1967) 1.22
The final step in the biosynthesis of hydrogenobyrinic acid is catalyzed by the cobH gene product with precorrin-8x as the substrate. J Bacteriol (1992) 1.20
Identification and analysis of genes from Streptomyces pristinaespiralis encoding enzymes involved in the biosynthesis of the 4-dimethylamino-L-phenylalanine precursor of pristinamycin I. Mol Microbiol (1997) 1.20
Primary structure, expression in Escherichia coli, and properties of S-adenosyl-L-methionine:uroporphyrinogen III methyltransferase from Bacillus megaterium. J Bacteriol (1991) 1.15
Biosynthesis of the corrin macrocycle of coenzyme B12 in Pseudomonas denitrificans. J Bacteriol (1993) 1.14
Minicircle: an improved DNA molecule for in vitro and in vivo gene transfer. Gene Ther (1999) 1.14
Purification, characterization, and molecular cloning of S-adenosyl-L-methionine: uroporphyrinogen III methyltransferase from Methanobacterium ivanovii. J Bacteriol (1991) 1.14
Precorrin-6x reductase from Pseudomonas denitrificans: purification and characterization of the enzyme and identification of the structural gene. J Bacteriol (1992) 1.13
pCOR: a new design of plasmid vectors for nonviral gene therapy. Gene Ther (1999) 1.13
Synthesis, activity, and structure--activity relationship studies of novel cationic lipids for DNA transfer. J Med Chem (1998) 1.13
The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum (2005) 1.13
Purification and partial characterization of Cob(I)alamin adenosyltransferase from Pseudomonas denitrificans. J Bacteriol (1991) 1.11
[D-penicillamine induced lupus during the treatment of rheumatoid arthritis. Report of 2 cases and systematic immunologic study during the treatment]. Ann Med Interne (Paris) (1974) 1.08
Genetic and sequence analyses of a Pseudomonas denitrificans DNA fragment containing two cob genes. J Bacteriol (1991) 1.08
Biosynthesis of vitamin B12: stepwise amidation of carboxyl groups b, d, e, and g of cobyrinic acid a,c-diamide is catalyzed by one enzyme in Pseudomonas denitrificans. J Bacteriol (1991) 1.08
Structural characteristics of supramolecular assemblies formed by guanidinium-cholesterol reagents for gene transfection. Proc Natl Acad Sci U S A (1999) 1.08
[Pemphigus induced by D-penicillamine in rheumatoid arthritis. Study of 5 cases and systematic study of anti-intercellular substance antibodies of the skin in the course of treatment]. Nouv Presse Med (1975) 1.07
Biosynthesis of vitamin B12 in Pseudomonas denitrificans: the biosynthetic sequence from precorrin-6y to precorrin-8x is catalyzed by the cobL gene product. J Bacteriol (1992) 1.06
Cloning and primary structure of the wide-spectrum amidase from Brevibacterium sp. R312: high homology to the amiE product from Pseudomonas aeruginosa. Gene (1992) 1.03
Snowmobile injuries in northern Newfoundland and Labrador: an 18-year review. J Trauma (1988) 1.03
[Epidemiological aspects of osteoarticular tuberculosis in adults. Retrospective study of 206 cases diagnosed in the Paris area from 1980 to 1994]. Presse Med (1997) 1.02
[100 cases of common rheumatoid polyarthritis, treated with D-penicillamin]. Ann Med Interne (Paris) (1974) 1.01
Topoisomerase I of Helicobacter pylori: juxtaposition with a flagellin gene (flaB) and functional requirement of a fourth zinc finger motif. Gene (1998) 0.99
[Penicillamine and rheumatoid polyarthritis (study of 9 cases)]. Ann Med Interne (Paris) (1970) 0.99
Streptogramin B biosynthesis in Streptomyces pristinaespiralis and Streptomyces virginiae: molecular characterization of the last structural peptide synthetase gene. Antimicrob Agents Chemother (1997) 0.99
Glycosylated flavones as selective inhibitors of topoisomerase IV. Antimicrob Agents Chemother (1997) 0.97
Efficient purification of plasmid DNA for gene transfer using triple-helix affinity chromatography. Gene Ther (1997) 0.96
[Research of an association between HL-A antigens and systemic scleroderma]. Nouv Presse Med (1975) 0.95
Erythropoietin secretion and physiological effect in mouse after intramuscular plasmid DNA electrotransfer. J Gene Med (2000) 0.94
Spondylodiscitis due to Candida species. J Rheumatol (1999) 0.93
Autoantibodies in D-penicillamine treated rheumatoid arthritis. Agents Actions (1976) 0.89
False-positive Aspergillus real-time PCR assay due to a nutritional supplement in a bone marrow transplant recipient with GVH disease. Med Mycol (2010) 0.89
Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group. Ann Intern Med (1995) 0.88
6-O-alpha-L-Arabinopyranosyl-beta-D-glucopyranosides as aroma precursors from passion fruit. Phytochemistry (1996) 0.87
An improved anion-exchange HPLC method for the detection and purification of adenoviral particles. Gene Ther (2000) 0.87
Long-term outcome of chronic hepatitis C in a population-based cohort and impact of antiviral therapy: a propensity-adjusted analysis. J Viral Hepat (2011) 0.85
Synthetic DNA-compacting peptides derived from human sequence enhance cationic lipid-mediated gene transfer in vitro and in vivo. Gene Ther (1999) 0.84
Mechanistic studies on AMD6221: a ruthenium-based nitric oxide scavenger. Biochem Biophys Res Commun (2002) 0.84
Construction of a broad-host-range non-mobilizable stable vector carrying RP4 par-region. Gene (1992) 0.83
Enamel remineralization as a factor in the pathogenesis of dental caries. J Oral Pathol (1980) 0.83
Effect of pH on retention of aroma compounds by beta-lactoglobulin. J Agric Food Chem (2000) 0.83
Nonsurgical treatment of osteoarticular tuberculosis. A retrospective study in 143 adults. Rev Rhum Engl Ed (1999) 0.82
[Fibroblastic rheumatism. A case with study of synovial histology]. Rev Rhum Mal Osteoartic (1982) 0.81
Production of a new DNA vehicle for gene transfer using site-specific recombination. Appl Microbiol Biotechnol (1998) 0.81
Osteoporotic fractures at presentation of Cushing's disease: two case reports and a literature review. Joint Bone Spine (2000) 0.81
Improvement of pCOR plasmid copy number for pharmaceutical applications. Appl Microbiol Biotechnol (2004) 0.81
[Familial scleroderma with Sjogren's syndrome and lymphocyte and chromosome abnormalities]. Ann Med Interne (Paris) (1970) 0.81
Ultraviolet B irradiation selectively increases the production of interleukin-8 in human cord blood-derived mast cells. Clin Exp Immunol (2007) 0.80
Stabilization of recombinant adenovirus: site-directed mutagenesis of key asparagine residues in the hexon protein. Anal Biochem (2001) 0.80
Polymorphisms in Toll-like receptors-2 and -4 are not associated with disease manifestations in acute Q fever. Genes Immun (2007) 0.80
Aliphatic nitrilase from a soil-isolated Comamonas testosteroni sp.: gene cloning and overexpression, purification and primary structure. Gene (1995) 0.80
Partial purification and initial studies of the tomato L-alanine:2-oxoglutarate aminotransferase. Biochim Biophys Acta (1974) 0.80
Application of lipids and plasmid design for gene delivery to mammalian cells. Curr Opin Biotechnol (1998) 0.80
[Arthralgias, cutaneous lesions and Raynaud's syndrome associated with myxoma of the left atrium]. Rev Rhum Mal Osteoartic (1987) 0.80
[Treatment of common rheumatoid polyarthritis with D-penicillamine. Study of a series of 22 cases]. Ann Med Interne (Paris) (1971) 0.79
[Pyrithioxine a new basic treatment of rheumatoid polyarthritis: initial study of 72 cases with a 6-month follow-up]. Rev Rhum Mal Osteoartic (1978) 0.79